Showing 4391-4400 of 9152 results for "".
- Maria Carell Named New CEO of Revision Skincare LLC, Goodier Cosmetics LLChttps://practicaldermatology.com/news/maria-carell-named-new-ceo-of-revision-skincare-llc-goodier-cosmetics-llc/2458223/Maria Carell is the new CEO of Revision Skincare® LLC and Goodier Cosmetics LLC. Ms. Carell's appointment follows the retirement of John Muller, the company's founder. Mr. Muller will retain hi
- Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategyhttps://practicaldermatology.com/news/allergan-names-daphne-karydas-as-senior-vice-president-of-global-investor-relations-strategy/2458224/Daphne Karydas is Allergan’s new Senior Vice President of Global Investor Relations and Strategy, effective April 17, 2017. In this role, Ms. Karydas will lead the Company's engagement with the investment community, and will work with
- Business News: Allergan and ZELTIQ Announce Expiration of HSR Waiting Period for Pending Transactionhttps://practicaldermatology.com/news/business-news-allergan-and-zeltiq-announce-expiration-of-hsr-waiting-period-for-pending-transaction/2458225/Allergan is now one step closer to officially acquiring Zeltiq. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has expired with respect to Allergan's proposed acquisition of ZELTIQ.
- Phase 4 Studies of Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefithttps://practicaldermatology.com/news/phase-4-studies-of-restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit/2458226/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Merz Taps Bob Rhatigan as New President, CEOhttps://practicaldermatology.com/news/merz-taps-bob-rhatigan-as-new-president-ceo/2458229/Allergan vet Bob Rhatigan is the new President and Chief Executive Officer (CEO) of Merz North America, and Patrick Urban will serve as Chief Commercial Officer, effective immediately. In his new role, Mr. Rhatigan will assume responsibility for Merz&rsq
- Novan Forms New Advisory Council Focused on Nitric Oxide Technologies in Dermatologyhttps://practicaldermatology.com/news/novan-forms-new-advisory-council-focused-on-nitric-oxide-technologies-in-dermatology/2458228/Novan, Inc. has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. These leading physicians will provide medical advice and drug-development insight to the Company’s senior leadership team and board of directors. The Advisory Council will
- No Antibiotics Needed For Mild Infected Eczema in Kidshttps://practicaldermatology.com/news/no-antibiotics-needed-for-mild-infected-eczema-in-kids/2458238/Oral or topical antibiotics are not effective for treating milder clinically infected eczema in children, a new study shows. In the study of 113 children with clinical, non-severely infected eczema, participants received either oral
- Dermalogica's Newest Add Targets Tired Eyeshttps://practicaldermatology.com/news/dermalogicas-newest-add-targets-tired-eyes/2458244/Dermalogica is launching their newest product – a two-in-one eye masque that targets tired eyes. The Stress Positive Eye Lift officially launches in early April 2017. Put on with a cooling massage applicator, this masque reduces the a
- ADAM Names Lori Skraba 2017 Practice Manager of the Yearhttps://practicaldermatology.com/news/adam-names-lori-skraba-2017-practice-manager-of-the-year/2458248/The Association of Dermatology Administrators and Managers (ADAM) named Lori Skraba of DuBois Dermatology and Cosmetics in DuBois, Pa., the recipient of the annual Practice Manager of the Year award. She was recognized at the 25th annual ADAM meeting in Orlando, FL. The ADAM Practice
- Serlopitant May Stop the Itch of Prurigo Nodularishttps://practicaldermatology.com/news/serlopitant-may-stop-the-itch-of-prurigo-nodularis/2458252/Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key sec